IAG Capital Partners

T-robotics uses end-to-end neural networks and constraint-based programming to train AI skills for robots. These skills are directly deployable on all major commercially available robot brands. These skills allow these robots to fail less, perform complex tasks, and program easily.

Ayar Labs, Inc. specializes in the development of optical interconnect technology, focusing on high-density electronic-photonic chiplets and lasers designed to enhance data transmission capabilities. Its flagship product, TeraPHY, is a monolithic in-package optical I/O solution that enables high bandwidth, low latency, and power-efficient short-reach interconnects, making it suitable for applications in artificial intelligence, high-performance computing, cloud computing, telecommunications, and aerospace. The company's innovative approach leverages industry-standard silicon processing techniques to create optical interconnect chiplets that replace traditional electrical-based I/O, addressing performance and efficiency challenges in the semiconductor and computing industries. By optimizing data movement within AI systems, Ayar Labs aims to alleviate compute and bandwidth bottlenecks associated with complex large language models, thereby maximizing computational efficiency while minimizing costs and power consumption. Established in 2015 and headquartered in Emeryville, California, Ayar Labs also has an office in Santa Clara, California.

Lightsynq develops universal optical quantum interconnects that bridge the gap to large-scale quantum computers.

MIRIS provides spatial material and allows users to communicate with digital content.

CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, it specializes in the development of bioresorbable smart polymers designed to enhance vascular surgery outcomes. The company’s primary product, SelfWrap, is a perivascular wrap that functions as an external stent, providing mechanical support to veins and promoting outward growth. This innovative technology aims to reduce complications at the vein-artery junction in dialysis patients, particularly by minimizing vein collapse and improving the usability of arteriovenous fistulas (AVF). By utilizing a new class of shape-memory polymers that do not require sutures, VenoStent's approach reduces surgery time and lowers the risk of infection, ultimately enhancing the quality and length of life for patients with chronic kidney disease undergoing hemodialysis.

Celestial AI is a prominent artificial intelligence company that provides an advanced platform for users to efficiently create images, text, and presentations. Utilizing computer vision algorithms and natural language processing, the platform produces high-quality visual and textual content. Its intuitive design and innovative features simplify the creation process, while intelligent data integration and a commitment to security ensure reliable results.

RIOS, founded in 2018, is a technology company helping global customers automate their factories, warehouses, and supply chain operations by deploying a new class of dexterous AI-powered robots. RIOS robots handle hard-to-automate tasks, typically requiring human-level dexterity, in unstructured environments. RIOS is headquartered in Palo Alto, CA and has a pilot facility in San Carlos, CA. More information is available at www.rios.ai.

NLX is a company that offers an end-to-end enterprise AI platform designed to enhance customer experiences for large brands. Its no-code, multimodal conversation platform allows organizations to create, monitor, and analyze automated conversations, leveraging machine learning and artificial intelligence. This technology enables personalized customer interactions through automated chat, voice, and multimodal conversations, facilitating effective self-service experiences. NLX's platform is highly scalable, integrated, and accessible anytime and anywhere, empowering brands to manage conversational deployments across their entire enterprise effectively.

Jana Care, Inc. is a Boston-based company that specializes in mobile point-of-care diagnostic solutions aimed at screening, managing, and monitoring chronic diseases. The company developed the Aina Device, a self-monitoring tool for patients to use at home, and the Aina Station, designed for clinics and hospitals. These devices enable a variety of tests, including blood glucose, HbA1c, lipid profiles, creatinine, and hemoglobin assessments. Additionally, Jana Care offers The Habits Program, a twelve-week digital coaching initiative for individuals managing diabetes and pre-diabetes. Founded in 2011, the company also has an office in Bengaluru, India, and emerged from a project initiated to create a smartphone app for health workers to screen for oral cancer and cardiovascular disease in rural communities.

Fantix operates a no-code network of companies focused on developing AI models through a collaborative learning approach. The company utilizes a data abstraction platform that enables federated insights and predictive customer AI while preserving consumer privacy and business confidentiality. By transforming data locally and comparing data abstractions, Fantix allows small and medium-sized businesses to analyze overlapping elements between datasets without sharing sensitive information. This method ensures that an aggregated and anonymous representation of data is maintained in a secure and encrypted manner, empowering businesses to uncover meaningful insights without compromising their data integrity.

Enfabrica is a technology company focused on developing innovative hardware and software solutions aimed at addressing the performance and scalability challenges of artificial intelligence (AI) and accelerated computing workloads. The company specializes in converged networking and memory fabric silicon, which are designed to enhance system efficiencies and performance across various infrastructures, including hyper-scale cloud, edge computing, enterprise systems, and automotive applications. By incorporating advanced technologies such as compute express link, Enfabrica enables businesses to optimize resources and manage multiple graphics processing units effectively. Its products and foundational fabric technologies are geared towards meeting the increasing demands of modern computing environments, particularly in the realm of AI and machine learning.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in real-time cellular activity monitoring for drug discovery and biological research. The company serves academic institutions and pharmaceutical companies by offering innovative systems designed for continuous and non-invasive measurement of cellular activities. Its flagship technology, RESIPHER, utilizes high-resolution optical oxygen sensors to monitor oxygen consumption within standard multi-well plates. This system provides researchers with valuable insights into cell culture experiments, streaming data directly to a user-friendly web application. By enhancing the understanding of cellular environments, Lucid Scientific aims to accelerate drug discovery and advance basic biological research.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, it specializes in the development of bioresorbable smart polymers designed to enhance vascular surgery outcomes. The company’s primary product, SelfWrap, is a perivascular wrap that functions as an external stent, providing mechanical support to veins and promoting outward growth. This innovative technology aims to reduce complications at the vein-artery junction in dialysis patients, particularly by minimizing vein collapse and improving the usability of arteriovenous fistulas (AVF). By utilizing a new class of shape-memory polymers that do not require sutures, VenoStent's approach reduces surgery time and lowers the risk of infection, ultimately enhancing the quality and length of life for patients with chronic kidney disease undergoing hemodialysis.

Celestial AI is a prominent artificial intelligence company that provides an advanced platform for users to efficiently create images, text, and presentations. Utilizing computer vision algorithms and natural language processing, the platform produces high-quality visual and textual content. Its intuitive design and innovative features simplify the creation process, while intelligent data integration and a commitment to security ensure reliable results.

Ayar Labs, Inc. specializes in the development of optical interconnect technology, focusing on high-density electronic-photonic chiplets and lasers designed to enhance data transmission capabilities. Its flagship product, TeraPHY, is a monolithic in-package optical I/O solution that enables high bandwidth, low latency, and power-efficient short-reach interconnects, making it suitable for applications in artificial intelligence, high-performance computing, cloud computing, telecommunications, and aerospace. The company's innovative approach leverages industry-standard silicon processing techniques to create optical interconnect chiplets that replace traditional electrical-based I/O, addressing performance and efficiency challenges in the semiconductor and computing industries. By optimizing data movement within AI systems, Ayar Labs aims to alleviate compute and bandwidth bottlenecks associated with complex large language models, thereby maximizing computational efficiency while minimizing costs and power consumption. Established in 2015 and headquartered in Emeryville, California, Ayar Labs also has an office in Santa Clara, California.

Graphiant Inc. is a technology company based in Silicon Valley, founded in 2020 and headquartered in Fremont, California. It specializes in developing software-defined wide area network (SD-WAN) solutions aimed at transforming enterprise networking. The company offers the Graphiant Network Edge, a software-as-a-service platform that facilitates seamless connectivity across enterprise WANs, hybrid clouds, network edges, and various clients and partners. Graphiant's technology combines the performance of traditional multiprotocol label switching with the agility of modern internet solutions, enabling network architects to design and implement enterprise-grade networks that keep pace with business demands.

Cognito Therapeutics is a clinical-stage neurotechnology company based in San Francisco, focused on developing disease-modifying treatments for neurodegenerative disorders, particularly Alzheimer's Disease. Founded by MIT professors Li-Huei Tsai and Ed Boyden, the company utilizes a non-invasive neuromodulation platform that induces brain wave oscillations to reactivate the brain's immune system. This innovative approach aims to address core symptoms of Alzheimer's by targeting and reducing the accumulation of amyloid plaques and tau tangles. Cognito's primary therapy is currently undergoing a pivotal study and has received designation as a Breakthrough Device from the FDA, highlighting its potential to significantly impact the treatment landscape for Alzheimer's patients.

NLX is a company that offers an end-to-end enterprise AI platform designed to enhance customer experiences for large brands. Its no-code, multimodal conversation platform allows organizations to create, monitor, and analyze automated conversations, leveraging machine learning and artificial intelligence. This technology enables personalized customer interactions through automated chat, voice, and multimodal conversations, facilitating effective self-service experiences. NLX's platform is highly scalable, integrated, and accessible anytime and anywhere, empowering brands to manage conversational deployments across their entire enterprise effectively.

Cornelis Networks, Inc. specializes in developing high-performance fabrics tailored for scientific, commercial, and government organizations. Founded in 2019 and headquartered in Wayne, Pennsylvania, the company provides network products that enhance computing, data analytics, and artificial intelligence workloads. Its solutions enable clients to harness the computational power of multiple processing devices concurrently, improving accuracy and results. Cornelis Networks serves a diverse clientele, with over 500 global installations across government agencies, academic institutions, and commercial enterprises, all aimed at advancing technological and scientific capabilities.

Leuko Labs focuses on developing a non-invasive device for monitoring white blood cell counts, which is crucial for various medical situations, including chemotherapy management and the detection of severe infections. Their device, PointCheck, allows for frequent testing without the need for blood draws or laboratory infrastructure, making it more accessible for patients. This innovation aims to enhance the quality of life for immunosuppressed individuals and improve clinical outcomes by enabling healthcare providers to offer personalized treatment plans based on real-time data. By simplifying the process of white blood cell assessment, Leuko Labs contributes to more effective patient management and better survival rates.

GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Ordaōs is a human-enabled, machine-driven drug design company. We create customized mini-proteins that help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods. miniPRO proteins are created and evaluated in silico, and then rigorously tested in vitro, which enables us to reliably and repeatedly deliver de novo solutions that meet our client’s stringent requirements at scale, including novelty and probability of clinical success. At Ordaōs, we help birth novel therapies that reduce patient suffering, improve health, and extend life.

Elucid, located in the Boston biotech and medtech hub, specializes in enhancing the accuracy and cost-effectiveness of cardiovascular diagnostic imaging through machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography (CTA) scan, aiding in the assessment of heart attack and stroke risk as well as treatment selection. The company also collaborates with pharmaceutical firms, healthcare providers, and research organizations to offer quantitative image analysis services. By applying artificial intelligence to vascular diagnostics, Elucid aims to improve patient outcomes while providing a non-invasive and economically efficient means of capturing critical health information, thereby supporting cardiovascular pathologists in delivering comprehensive clinical insights.

Ayar Labs, Inc. specializes in the development of optical interconnect technology, focusing on high-density electronic-photonic chiplets and lasers designed to enhance data transmission capabilities. Its flagship product, TeraPHY, is a monolithic in-package optical I/O solution that enables high bandwidth, low latency, and power-efficient short-reach interconnects, making it suitable for applications in artificial intelligence, high-performance computing, cloud computing, telecommunications, and aerospace. The company's innovative approach leverages industry-standard silicon processing techniques to create optical interconnect chiplets that replace traditional electrical-based I/O, addressing performance and efficiency challenges in the semiconductor and computing industries. By optimizing data movement within AI systems, Ayar Labs aims to alleviate compute and bandwidth bottlenecks associated with complex large language models, thereby maximizing computational efficiency while minimizing costs and power consumption. Established in 2015 and headquartered in Emeryville, California, Ayar Labs also has an office in Santa Clara, California.

Lindy Biosciences, LLC is a development-stage company based in Durham, North Carolina, specializing in protein-based therapeutic formulations. Utilizing a technology known as microglassification, the company gently removes a significant portion of water from solutions of proteins and other biologics, resulting in solid, spherical, amorphous microbeads. These microbeads create stable, dense particles of therapeutic proteins suitable for various applications, including high-concentration injectable suspensions, encapsulation for controlled release, and long-term storage. Established in 2016, Lindy Biosciences aims to provide innovative solutions for the formulation of protein therapeutics, addressing the needs of medical researchers in developing advanced therapeutic options.

CaliberMind is a developer of a B2B customer data platform designed to enhance the effectiveness of revenue marketers. The platform offers a range of features, including marketing attribution, engagement scoring, and insights into sales funnels and pipeline conversion points. It also provides tools for data integration, account engagement, and marketing workflow automation, allowing companies to leverage their sales, marketing, and customer data more effectively. By doing so, CaliberMind aims to help businesses optimize productivity, improve customer engagement, and ultimately increase revenue.

BeatBread is an innovative music and finance company founded in 2020 that aims to empower independent and unsigned artists by providing them with financial advances while allowing them to retain ownership of their music and decision-making power. The company has assembled a team with extensive expertise in music, finance, artificial intelligence, and machine learning to create new opportunities for artists and their managers. BeatBread's platform offers artists the flexibility to choose how they repay the financial advances, which are derived from a limited share of their revenues generated through streaming and airplay. This approach enables musicians to advance their careers on their own terms, fostering greater independence and control in the music industry.

Tethr enables the enterprise to make smarter business decisions based on the true Voice of the Customer, with an AI-driven communications intelligence platform that listens to and analyzes every customer conversation and surfaces contextual understanding and insights from the data. Based on over a decade of best-practice CX research, Tethr gives organizations the ability to measure what matters and share the voice of the customer insights across the organization to directly impact sales results, customer loyalty, operating costs, compliance, and risk.

GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

First Ascent Biomedical is a biotechnology company focused on enhancing cancer treatment through artificial intelligence. The company has developed a drug prediction platform that leverages AI and therapy-resistant cell technologies to create personalized treatment plans for oncology patients. By analyzing individual patients' cancer cells in conjunction with FDA-approved drugs, First Ascent Biomedical aims to offer affordable treatment options while minimizing the likelihood of failed treatment regimens. Additionally, the platform provides valuable insights into biomarker discovery and facilitates the development of trial populations, thereby supporting both patients and pharmaceutical companies in the quest for more effective cancer therapies.

New View Surgical, Inc. is a medical device company based in Boston, Massachusetts, that specializes in the development and commercialization of the VisionPort technology. This innovative system consolidates four essential surgical devices—a laparoscope, camera, light source, and access port—into a single, easy-to-use, and disposable unit. The VisionPort system aims to enhance minimally invasive surgical procedures by providing surgeons with complete control over visualization and instrumentation. Founded in 2009, the company is led by a team of experienced professionals dedicated to addressing unmet needs in the medical field, offering potential clinical and economic advantages for operating rooms worldwide.

Elucid, located in the Boston biotech and medtech hub, specializes in enhancing the accuracy and cost-effectiveness of cardiovascular diagnostic imaging through machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography (CTA) scan, aiding in the assessment of heart attack and stroke risk as well as treatment selection. The company also collaborates with pharmaceutical firms, healthcare providers, and research organizations to offer quantitative image analysis services. By applying artificial intelligence to vascular diagnostics, Elucid aims to improve patient outcomes while providing a non-invasive and economically efficient means of capturing critical health information, thereby supporting cardiovascular pathologists in delivering comprehensive clinical insights.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, it specializes in the development of bioresorbable smart polymers designed to enhance vascular surgery outcomes. The company’s primary product, SelfWrap, is a perivascular wrap that functions as an external stent, providing mechanical support to veins and promoting outward growth. This innovative technology aims to reduce complications at the vein-artery junction in dialysis patients, particularly by minimizing vein collapse and improving the usability of arteriovenous fistulas (AVF). By utilizing a new class of shape-memory polymers that do not require sutures, VenoStent's approach reduces surgery time and lowers the risk of infection, ultimately enhancing the quality and length of life for patients with chronic kidney disease undergoing hemodialysis.

CoreCare, Inc. operates an AI-driven software as a service platform tailored for the senior living industry, specifically for Post-Acute and Long-Term Care providers. Founded in 2019 and based in Fort Worth, Texas, the company offers CoreAccess, a solution that simplifies the billing process and alleviates financial complexities for healthcare providers. This platform consolidates provider and payor information systems, standardizing scattered data to identify and rectify inconsistencies efficiently. CoreCare’s CoreAccess Portal aggregates Managed Care Organization data, facilitating easier preparation, submission, reconciliation, and reconsideration of reimbursements. The platform is designed to enhance operational efficiency by increasing admissions, optimizing reimbursement rates, and improving collection metrics, while also reducing administrative burdens. CoreCare has gained the trust of over 1,000 locations nationwide and is backed by Y Combinator, positioning itself as a leader in AI applications for long-term care.

Obsidio, Inc. is a medical device company founded in 2018 and based in Solana Beach, California. The company specializes in developing shear-thinning hydrogel biomaterial technology, which is used to manufacture therapeutic devices and universal gel embolization materials. This technology allows for minimally invasive procedures to inject embolic materials through catheters, effectively stopping undesirable blood flow in vessels throughout the body. Obsidio's products are applicable in various medical scenarios, including the treatment of hemorrhages, aneurysms, and tumors, as well as managing conditions related to coagulopathy. By focusing on interventional radiology and oncology, Obsidio aims to provide precise and durable solutions for vascular occlusion.

Zopa is a peer-to-peer lending platform that connects lenders directly with borrowers, eliminating the need for traditional banks as intermediaries. This service allows individuals to invest their savings by lending small amounts to multiple borrowers, thereby spreading risk. Zopa offers an app to help users manage their loans, credit cards, and savings, while also providing tools to monitor their credit scores. The company mitigates risk for lenders through measures such as mandatory monthly direct debit repayments and legal contracts with borrowers. Zopa generates revenue by charging borrowers a fixed fee and a 1% annual fee for lenders. The platform has received several accolades for its innovation and customer service, highlighting its reputation in the financial technology sector.

Tethr enables the enterprise to make smarter business decisions based on the true Voice of the Customer, with an AI-driven communications intelligence platform that listens to and analyzes every customer conversation and surfaces contextual understanding and insights from the data. Based on over a decade of best-practice CX research, Tethr gives organizations the ability to measure what matters and share the voice of the customer insights across the organization to directly impact sales results, customer loyalty, operating costs, compliance, and risk.

Lindy Biosciences, LLC is a development-stage company based in Durham, North Carolina, specializing in protein-based therapeutic formulations. Utilizing a technology known as microglassification, the company gently removes a significant portion of water from solutions of proteins and other biologics, resulting in solid, spherical, amorphous microbeads. These microbeads create stable, dense particles of therapeutic proteins suitable for various applications, including high-concentration injectable suspensions, encapsulation for controlled release, and long-term storage. Established in 2016, Lindy Biosciences aims to provide innovative solutions for the formulation of protein therapeutics, addressing the needs of medical researchers in developing advanced therapeutic options.

Grips Intelligence is an e-commerce market research platform that delivers critical insights to manufacturers, retailers, and investors, enabling them to pinpoint growth opportunities. The platform leverages advanced machine learning technology to convert data and signals from websites into actionable products for brands and e-retailers. Its capabilities include website categorization and cross-domain product mapping, which facilitate data-driven performance marketing. By providing transactional intelligence data, Grips Intelligence supports thousands of businesses worldwide in optimizing their online sales performance and maximizing their potential in the competitive e-commerce landscape.

Path Ex, Inc. is a Nashville-based company established in 2017 that specializes in the development of extracorporeal blood-cleansing equipment aimed at treating sepsis, a severe and often fatal condition linked to blood-borne infections. The company has created a proprietary technology that selectively separates and captures bacteria and toxins from human blood, offering a novel approach to treatment. Unlike traditional methods that rely on broad-spectrum antibiotics to kill infections, Path Ex's device effectively removes intact bacteria from the bloodstream, regardless of the bacteria type or antibiotic resistance. This innovative technology has the potential to improve patient outcomes by reducing diagnostic times, treatment costs, readmission rates, and fatalities associated with sepsis.

Graphiant Inc. is a technology company based in Silicon Valley, founded in 2020 and headquartered in Fremont, California. It specializes in developing software-defined wide area network (SD-WAN) solutions aimed at transforming enterprise networking. The company offers the Graphiant Network Edge, a software-as-a-service platform that facilitates seamless connectivity across enterprise WANs, hybrid clouds, network edges, and various clients and partners. Graphiant's technology combines the performance of traditional multiprotocol label switching with the agility of modern internet solutions, enabling network architects to design and implement enterprise-grade networks that keep pace with business demands.